What ЭФКУРИЯ Treats: Main Uses and Benefits

This medication is commonly used to help manage BH₄-responsive Hyperphenylalaninemia (HPA), a condition presenting with systemic or localized discomfort. This treatment is applied across conditions where functional stability becomes affected by this excess amino acid, including responsive forms of Phenylketonuria (PKU) and BH4 deficiency.

---

Core Therapeutic Domains

This medicine is commonly used to help manage the fundamental metabolic disorder. The core therapeutic domains include:

• Addressing systemic imbalance: The primary therapeutic benefit contributes to easing the overall symptom load associated with systemic imbalance.
• Support for Neurocognitive Well-being: It is relevant for managing symptoms of increased neurological or muscular activity. This treatment supports the patient's general well-being, which is especially relevant for pediatric patients and women with PKU during pregnancy.
• Assistance with dietary management: Supporting functional stability related to dietary requirements.

The benefit of using this therapy is primarily one of support: “The primary purpose is to provide support that helps patients cope more steadily with symptom fluctuations.”

---

Quick Facts: Primary Patient Benefit

Quick Fact: Relief for Metabolic Symptoms	Description
Primary Goal	Assisting with management of symptoms related to systemic imbalance.
Key Patient Advantage	May increase tolerance for dietary protein.
Relevant Clinical Context	Chronic, lifelong metabolic management.

Regulatory References

1. Clinical Review Report: Sapropterin dihydrochloride (Kuvan) - NIH Bookshelf

The eligibility profile for ЭФКУРИЯ (Sapropterin Dihydrochloride) is strictly defined by regulatory criteria, focusing on responsiveness status and specific patient health conditions.

Populations Allowed and Contraindicated

The medicine is approved for use in adult patients and pediatric patients aged one month and older who have been diagnosed with Hyperphenylalaninemia (HPA) due to Tetrahydrobiopterin (BH₄)-responsive Phenylketonuria (PKU). Eligibility for treatment is conditional upon confirmed biochemical responsiveness. Use of ЭФКУРИЯ is contraindicated in patients with a known hypersensitivity to the active substance or excipients. Treatment must be discontinued in patients who are confirmed as non-responders to the therapy.

Condition-Specific Restrictions

Conditional use applies to several groups where data is limited or caution is required. Use is not recommended in patients with severe renal impairment due to a lack of established safety data; caution is advised in mild to moderate impairment. Data is limited concerning use in older adults (65 years and over). Use during pregnancy and breastfeeding is generally not recommended unless clearly needed, reflecting regulatory caution. Caution is also necessary for patients with a history of oesophagitis, gastritis, or GERD.

The regulatory documentation for ЭФКУРИЯ (Sapropterin Dihydrochloride) outlines several defined interaction patterns with other medicines and products, though no formal contraindicated combinations are explicitly listed.

Pharmacodynamic and Transporter Interactions

The medicine's official profile includes interactions based on pharmacodynamic and pharmacokinetic mechanisms. Co-administration with Phosphodiesterase-5 (PDE-5) Inhibitors (such as Sildenafil or Vardenafil) may result in additive vasorelaxation, which carries a documented risk of hypotension (low blood pressure). Separately, the medicine acts as an inhibitor of the P-glycoprotein (P-gp) efflux transporter, leading to increased systemic exposure of co-administered P-gp substrates, such as Betrixaban.

---

Metabolic and Administration Constraints

A metabolic interaction is documented with Folate Metabolism Inhibitors (e.g., Methotrexate, Trimethoprim). These agents may reduce the levels of endogenous Tetrahydrobiopterin ( BH4) by disrupting the enzyme pathway involved in its recycling, which necessitates increased monitoring of blood Phenylalanine ( Phe) levels. The regulatory label specifies a non-timing-based administration requirement with food to ensure adequate systemic absorption and overall drug exposure. A population-specific caution exists for Levodopa co-administration in patients with underlying neurologic disorders, due to reports of central nervous system effects, including over-stimulation.

The mechanism of ЭФКУРИЯ (Sapropterin Dihydrochloride) is highly targeted, operating as an enzyme co-factor replacement and enhancer therapy to modulate a specific metabolic pathway.

Co-factor Replacement and Enzyme Stabilization

The drug is a synthetic analog of the naturally occurring essential co-factor Tetrahydrobiopterin (BH4). Its primary action is to bind to and stabilize the structurally compromised Phenylalanine Hydroxylase (PAH) enzyme. This chemical chaperone effect enhances the residual catalytic activity of PAH, which is necessary for L-phenylalanine catabolism.

Modulation of Amino Acid Catabolism and Systemic Clearance

By stabilizing PAH, the mechanism accelerates the enzyme's ability to convert L-phenylalanine into L-tyrosine—the rate-limiting step in this catabolic pathway. This promotes the metabolic conversion of L-phenylalanine, leading to a net decrease in the concentration of L-phenylalanine in the plasma and tissues. This physiological change represents the core mechanistic output.

Support for Neurochemical Pathway Regulation

Beyond PAH, the supplemented BH4 co-factor is also required for other interconnected enzymes, including Tyrosine Hydroxylase and Tryptophan Hydroxylase. The presence of the co-factor indirectly supports the necessary biosynthesis of key monoamine neurotransmitters (like Dopamine and Serotonin), contributing to the regulation of biogenic amine levels within the central nervous system.

ЭФКУРИЯ is administered exclusively through the oral route, utilizing the available tablets or powder which are designed to be dissolved into a solution. The correct use of this medicine is structured by a mandatory weight-based dosing principle, where the prescribed amount is calculated in milligrams per kilogram (mg/kg) of the patient's body weight, with a consistent upper limit of 20 mg/kg per day.

The medicine is typically scheduled for administration once daily for patients with PKU. To optimize the intake conditions, the dose must be consumed with a meal, preferably at the same time each day. This timing ensures proper absorption. The tablets or powder must be dissolved entirely in water or apple juice and then ingested rapidly, generally within 15 to 30 minutes of preparation, a constraint necessary to maintain the integrity of the solution.

For specific populations, the administration pattern may be adjusted; for instance, the total daily dose for BH4 deficiency may be divided into two or three separate administrations. For children aged one month to six years, the standard starting dose is set at 10 mg/kg once daily. Prior to confirming chronic, long-term use, an initial therapeutic trial lasting up to one month is required to evaluate the patient's biochemical response. If a daily dose is missed, the missed dose is taken as soon as possible, but it is strictly forbidden to take two doses on the same day.

Research Evidence / Overview of Studies for ЭФКУРИЯ

ЭФКУРИЯ (Sapropterin Dihydrochloride) has been evaluated in a structured research program to understand its role in metabolic support. This summary focuses only on the official research base, including the design and reported measurements of studies, without offering clinical advice or treatment instructions.

---

Evidence for Use in BH₄-Responsive Hyperphenylalaninemia (HPA) and PKU

Clinical research for this compound was primarily collected in short-term Randomized, Double-Blind, Placebo-Controlled Trials (RCTs). These pivotal studies were applied in research contexts involving patients with confirmed BH₄-responsive Hyperphenylalaninemia (HPA), including those with Phenylketonuria (PKU). Researchers primarily examined changes in the concentration of the biomarker blood Phenylalanine (Phe), which is a monitored physiological indicator.

The studies explored short-term changes and monitored whether the use of the compound was associated with measured shifts in the key biomarker. Studies reported patterns observed where measurements of blood Phe levels in responsive patients differed from those in the placebo group over the course of the research. Additionally, research examined whether there were measured differences in the amount of dietary Phe (natural protein intake) patients maintained. These findings help contextualize measured dietary patterns within the study settings.

What outcomes were measured in the pivotal trials?

Beyond the primary biomarker, studies monitored other physiological outcomes related to daily functioning and long-term well-being. Researchers tracked standard measures of physical growth, such as height, weight, and head circumference, particularly in younger participants. Furthermore, specific studies monitored certain neurocognitive and developmental outcomes to assess how these functional measures evolved in the observed populations during the study period. These evaluations were used in research exploring how symptoms are measured across conditions marked by functional limitations.

---

Long-Term Research and Follow-up Evidence

While the core regulatory findings are based on short-term RCTs, the broader evidence landscape includes Open-Label Extension Studies and longer-term Observational Studies. These follow-up studies were used to explore sustained measurements and monitor patient responses over defined time intervals, extending up to two years or more in some cohorts.

These extended studies continued to monitor blood Phe levels and dietary tolerance. Findings contribute to the broader evidence landscape regarding long-term metabolic monitoring. However, certainty remains low and evidence is limited regarding the compound's long-term influence on quality of life and complex neurocognitive outcomes over decades, as these aspects require extensive follow-up that is often challenging to capture in controlled settings. Data are still emerging, and research is ongoing to better establish these long-term functional axes.

---

Evidence in Special Age Groups

The research for ЭФКУРИЯ was designed to include patients across the entire relevant age spectrum. Adults and adolescents were evaluated in the primary pivotal trials, and studies specifically included groups of younger children and infants (those under four years old).

Research was designed to examine the applicability of study methodologies across different age groups with BH₄-responsive HPA. Results apply only to the populations studied, and findings were based on modest sample sizes in certain pediatric subgroups. Research provides context but not individual predictions, and the available data for certain younger age groups, while sufficient for regulatory review, remains more limited than for the broader adult and adolescent populations.

---

What is Still Uncertain About the Research for ЭФКУРИЯ?

While the evidence contributes to the broader understanding of managing BH₄-responsive HPA, several limitations and uncertainties have been noted in the scientific literature:

• Follow-up Durations: The most definitive results regarding blood Phe shifts are derived from studies where follow-up durations were limited (weeks-long). The long-term effects of sustained use are not fully established by the highest quality, controlled evidence.
• Population Specificity: The research focuses on the BH₄-responsive population; findings may not be representative of the wider HPA population who do not exhibit responsiveness.
• Functional Outcomes: There is limited information for long-term functional outcomes, such as the durability of cognitive support and day-to-day activity level measurements. While studies monitored these outcomes, controlled, large-scale data spanning many years are still insufficient.
• Evidence Quality: Although the core studies are RCTs, evidence quality varies across the observational and post-hoc studies that explore secondary and longer-term outcomes. The subgroup findings, particularly for specific developmental milestones, are uncertain.

Key Studies & References

1. Sapropterin dihydrochloride (Kuvan) - Clinical Review Report
2. Safety and Efficacy of Sapropterin in Hyperphenylalaninemia: A Systematic Review and Meta-Analysis

Common questions about ЭФКУРИЯ (FAQ)

---

Q: What is the recommended maximum shelf life for the tablets after I first open the bottle?

According to official product information, regulatory documents recommend discarding any remaining tablets 2 months (60 days) after the bottle is first opened. It is important to keep the cap tightly closed between uses to protect the medicine from moisture.

---

Q: What are the common side effects that I might experience?

Regulatory documents list side effects based on how often they occurred in clinical trials. Very common reactions, occurring in ge 1 in 10 patients, include headache, runny nose (rhinorrhea), and throat pain (pharyngolaryngeal pain). Common reactions, occurring in ge 1% to < 10% of patients, include diarrhea, vomiting, cough, and nasal congestion.

---

Q: Does taking this drug require any special monitoring of blood work or lab tests?

Official regulatory guidance indicates that active management often includes regular clinical assessment and monitoring. This monitoring may include frequent checks of blood Phenylalanine ( Phe) and Tyrosine levels. This process evaluates the overall metabolic control and nutritional balance.

---

Q: Can I mix the dissolved medicine with anything other than water or apple juice, like soda or milk?

Official administration instructions specify dissolving the tablets only in water or apple juice. The regulatory information also notes that the crushed tablets may be mixed with soft foods, such as applesauce or pudding, if following specific product instructions.

---

Q: Is it okay to crush the tablets instead of dissolving them in liquid?

Regulatory product information indicates that the tablets may be crushed to help them dissolve more quickly in liquid (water or apple juice). The tablets can also be crushed and mixed with soft foods for administration, following the official product guidelines.

---

Q: How long does it take for ЭФКУРИЯ to start working after I take my first dose?

Official studies and regulatory information do not focus on the immediate effects after a single dose. A response to the therapy is determined after an initial therapeutic trial period, which typically lasts up to one month. During this time, blood Phenylalanine ( Phe) levels are monitored to evaluate the biochemical response to the therapy.

How to Store and Dispose of ЭФКУРИЯ (Sapropterin Dihydrochloride)

Storage Requirements

ЭФКУРИЯ tablets must be stored at room temperature, specifically between 20 C to 25 C (68 F to 77 F), and must not be frozen. Keep the tablets in the original container with the cap tightly closed to protect the medicine from moisture. The bottle's desiccant must not be removed or swallowed. Keep the medicine out of the reach and sight of children.

Stability and Disposal

Discard any remaining tablets 2 months (60 days) after the bottle is first opened. The prepared solution must be used or discarded within 15 to 20 minutes after dissolving the tablet. Dispose of any unused or expired medication in accordance with local and national pharmaceutical waste regulations, and avoid throwing the product into household trash or wastewater.